The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer
Immune checkpoint inhibitors are frequently used to treat advanced non-small cell lung cancer (NSCLC). Drug clearance also varies depending on patient-related factors. Therefore, the lung immune prognostic index (LIPI), based on inflammatory markers, may help predict prognosis. Early changes in LIPI may predict treatment response and survival. This multicenter study included 707 patients with NSCLC. LIPI was calculated at baseline and one month after treatment initiation. Patients were categorized into two groups: those with stable or improved LIPI scores and those with worsened LIPI scores. Survival outcomes and prognostic significance were analyzed. Median progression free survival was 9 months in patients with stable or improved LIPI and 6 months in those with worsened LIPI (p = 0.005). Median overall survival was 15 months in the stable/improved LIPI group and 9 months in the worsened LIPI group (p = 0.001). Changes in LIPI can be assessed using routine laboratory tests as early as the second treatment cycle, allowing early prediction of treatment response. Baseline LIPI values and changes in LIPI can predict prognosis.
Authors
- M. Erman
- Sedat Yıldız (ORCID: https://orcid.org/0000-0002-7872-790X)
- Teoman Şakalar (ORCID: https://orcid.org/0000-0003-2749-9414)
- Latif Karahan (ORCID: https://orcid.org/0000-0001-5238-0883)
- Tolga Köşeci (ORCID: https://orcid.org/0000-0002-8696-0525)
- Berrak Mermit Erçek (ORCID: https://orcid.org/0000-0003-1058-5500)
- muslih urun
- Elif Şahin (ORCID: https://orcid.org/0000-0002-1976-3951)
- Cengiz Akosman (ORCID: https://orcid.org/0000-0003-3668-5550)
- Hayati Arvas (ORCID: https://orcid.org/0000-0003-2215-5567)
- Sedat Biter (ORCID: https://orcid.org/0000-0002-1053-0668)
- Deniz Can Güven (ORCID: https://orcid.org/0000-0002-6924-9467)
- Mustafa Ersoy (ORCID: https://orcid.org/0000-0001-9035-4846)
- Muhammet Cengiz (ORCID: https://orcid.org/0000-0002-2028-9687)
- Duygu Bayir
- Metin Özkan
- Aslihan Ezgi Apaydin Rollas
- Erdem Kolemen
- Saadettin Kilickap
- Sedat Yildirim
- Nargiz Majidova
- Emel Mutlu Ozkan
- Hacer Demir
- Ayse Nuransoy Cengiz
- Devrim Cabuk
- Anıl Karakayali
- Umut Kefeli
- Mehmet Mutlu Kidi
- Pervin Can Sanci
- H. Yesil Cinkir
- Erkam Kocaaslan
- Mevlude Inanc
- Ezgi Turkoğlu
- Gözde Agdas
Institutions
- Van Yüzüncü Yıl Üniversitesi (TR)
- Dicle University (TR)
- Heidelberg University (DE)
- Hitit Üniversitesi (TR)
- University Hospital Heidelberg (DE)
- Kütahya Dumlupınar Üniversitesi (TR)
- Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR)
- Istinye University (TR)
- Afyonkarahisar Sağlık Bilimleri Üniversitesi
- Maltepe University (TR)
- Kahramanmaraş Sütçü İmam University (TR)
- Eskişehir Osmangazi University (TR)
- Kocaeli Üniversitesi (TR)
- Afyon Kocatepe University (TR)
- Cukurova University (TR)
- Gaziantep University (TR)
- Ordu University (TR)
- Hacettepe University (TR)
- Marmara University (TR)
- Erciyes University (TR)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1007/s12672-026-04705-x
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00